Your browser doesn't support javascript.
loading
Macrophage GSK3ß-deficiency inhibits the progression of hepatocellular carcinoma and enhances the sensitivity of anti-PD1 immunotherapy.
Sun, Guangshun; Liu, Hanyuan; Zhao, Jie; Zhang, Jinyu; Huang, Tian; Sun, Guoqiang; Zhao, Siqi; Zhang, Zihao; Cao, Hengsong; Rong, Dawei; Kong, Xiangyi; Ji, Qinghua; Liu, Li; Wang, Xuehao; Tang, Weiwei; Xia, Yongxiang.
Afiliação
  • Sun G; Hepatobiliary/Liver Transplantation Center, The First Affiliated Hospital of Nanjing Medical University, Key Laboratory of Living Donor Transplantation, Chinese Academy of Medical Sciences, Nanjing, Jiangsu, China.
  • Liu H; Department of General Surgery, Nanjing First Hospital, Nanjing Medical University, Nanjing, Jiangsu, China.
  • Zhao J; Department of General Surgery, Nanjing First Hospital, Nanjing Medical University, Nanjing, Jiangsu, China.
  • Zhang J; Hepatobiliary/Liver Transplantation Center, The First Affiliated Hospital of Nanjing Medical University, Key Laboratory of Living Donor Transplantation, Chinese Academy of Medical Sciences, Nanjing, Jiangsu, China.
  • Huang T; Jiangsu Key Laboratory of Infection and Immunity, Institute of Biology and Medical Sciences, Soochow University, Suzhou, Jiangsu, China, Suzhou, Jiangsu, China.
  • Sun G; Hepatobiliary/Liver Transplantation Center, The First Affiliated Hospital of Nanjing Medical University, Key Laboratory of Living Donor Transplantation, Chinese Academy of Medical Sciences, Nanjing, Jiangsu, China.
  • Zhao S; Department of General Surgery, Nanjing First Hospital, Nanjing Medical University, Nanjing, Jiangsu, China.
  • Zhang Z; Department of General Surgery, Nanjing First Hospital, Nanjing Medical University, Nanjing, Jiangsu, China.
  • Cao H; Hepatobiliary/Liver Transplantation Center, The First Affiliated Hospital of Nanjing Medical University, Key Laboratory of Living Donor Transplantation, Chinese Academy of Medical Sciences, Nanjing, Jiangsu, China.
  • Rong D; Hepatobiliary/Liver Transplantation Center, The First Affiliated Hospital of Nanjing Medical University, Key Laboratory of Living Donor Transplantation, Chinese Academy of Medical Sciences, Nanjing, Jiangsu, China.
  • Kong X; Hepatobiliary/Liver Transplantation Center, The First Affiliated Hospital of Nanjing Medical University, Key Laboratory of Living Donor Transplantation, Chinese Academy of Medical Sciences, Nanjing, Jiangsu, China.
  • Ji Q; Hepatobiliary/Liver Transplantation Center, The First Affiliated Hospital of Nanjing Medical University, Key Laboratory of Living Donor Transplantation, Chinese Academy of Medical Sciences, Nanjing, Jiangsu, China.
  • Liu L; Zhejiang Puluoting Health Technology Co., Ltd, Hangzhou, Zhejiang, China.
  • Wang X; First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin, China yx_xia@njmu.edu.cn 1243773473twww@sina.com wangxh@njmu.edu.cn jewtou@gmail.com.
  • Tang W; State Key Laboratory of Modern Chinese Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin, China.
  • Xia Y; Hepatobiliary/Liver Transplantation Center, The First Affiliated Hospital of Nanjing Medical University, Key Laboratory of Living Donor Transplantation, Chinese Academy of Medical Sciences, Nanjing, Jiangsu, China yx_xia@njmu.edu.cn 1243773473twww@sina.com wangxh@njmu.edu.cn jewtou@gmail.com.
J Immunother Cancer ; 10(12)2022 12.
Article em En | MEDLINE | ID: mdl-36600662
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Carcinoma Hepatocelular / Neoplasias Hepáticas Idioma: En Ano de publicação: 2022 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Carcinoma Hepatocelular / Neoplasias Hepáticas Idioma: En Ano de publicação: 2022 Tipo de documento: Article